NSCLC
Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori
June 28, 2018Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma
UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …
AstraZeneca’s Imfinzi becomes India’s first available immunotherapy for lung cancer
June 22, 2018Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, India, NSCLC, lung cancer, pharma
In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi (durvalumab) has secured approval in …
BMS’ Opdivo becomes first immuno-oncology agent available in China
June 18, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma
Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …
Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3
May 29, 2018Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq
Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …
AZ’s Imfinzi hits second major milestone at Phase 3 in unresectable lung cancer
May 25, 2018Medical Communications, Research and Development AstraZeneca, Imfinzi, NSCLC, lung cancer, pharma
AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi …
AZ’s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer
April 19, 2018Sales and Marketing AstraZeneca, Cancer, EGFR-TKIs, NSCLC, Tagrisso, lung cancer, pharma
AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …
Keytruda success continues, beating Opdivo in lung cancer survival
April 17, 2018Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD …
Keytruda scores big as a first-line monotherapy in NSCLC patients with any level of PD-L1 expression
April 10, 2018Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
Closely following the news that Keytruda (pembrolizumab) had failed in the treatment of unresectable or metastatic melanoma as a combination …
BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression
February 6, 2018Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …
Pfizer’s Xalkori sees rejection at the hands of NICE in lung cancer
January 19, 2018Medical Communications, Sales and Marketing Cancer, NCIE, NSCLC, Pfizer, UK, Xalkori, lung cancer, pharma
UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …
Boehringer’s Gilotrif approved in US for lung cancer with non-resistant EGFRs
January 16, 2018Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, Cancer, FDA, Giltrif, NSCLC, lung cancer
Boehringer Ingelheim is celebrating the FDA’s decision to expand the indication of its lung cancer drug Gilotrif (afatinib) to include …
Moffitt scientists discover new applications for Novartis’s Zykadia
October 11, 2017Research and Development Cancer, Moffitt, NSCLC, ceritinib, lung cancer, zykadia
Through the use of molecular screening, functional proteomics and computer-based modelling, researchers from the Moffitt Cancer Center have been working …
AstraZeneca’s Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC
October 9, 2017Sales and Marketing AstraZeneca, Cancer, NSCLC, immunotherapy, lung cancer
AstraZeneca has announced that its targeted therapy, Tagrisso (osimertinib), has been awarded Breakthrough Therapy Designation by the FDA for the …
AstraZeneca’s Tagrisso beats standard of care in halting NSCLC
September 11, 2017Research and Development, Sales and Marketing AstraZeneca, ESMO, NSCLC, Tagrisso, non-small cell cell cancer, pharma, pharmaceutical
AstraZeneca has revealed new data at the European Society of Medical Oncology (ESMO) on the efficacy of Tagrisso (osimertinib) in …
Novartis gains first-line approval for Zykadia in lung cancer
June 29, 2017Research and Development EMA, European Commission, NSCLC, Novartis
The European Commission has followed the EMA’s CHMP positive opinion by approving Novartis’ Zykadia for first-line treatment of patients with …
Latest content
Five Facts about cardiovascular disease
